Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659880 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1713616 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL12316010 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL27626477 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL739575 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL1263214 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL523698 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL3659883 | 1.00 | KMT2A (1.00) | KMT2AMAPTMAPK1ALOX15CASP1 | |
| SCHEMBL522714 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB | |
| SCHEMBL522715 | 0.90 | KMT2A (0.81) | KMT2AMAPTMAPK1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237903-B1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RES & ENG CO (US) | 2020-02-26 | — | — | EP | claimed |
| EP-3237903-A1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | Exxonmobil Research And Engineering Company (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160187314-A1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-30 | — | — | US | claimed |
| WO-2016106211-A1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160187315-A1 | METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-30 | — | — | US | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3237903-B1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RES & ENG CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160187314-A1 | METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160187315-A1 | METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| CN-1764456-A | Treatment of related diseases using full alpha-7 nACh receptor agonists | PHARMACIA & UPJOHN CO LLC (US) | 2006-04-26 | — | — | CN | disclosed |
| US-5864039-A | THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0774460-A1 | BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| US-5281612-A | Naphthyridine antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| US-4771054-A | QUINOLINE CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| US-4665079-A | QUINOLINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPT 3971/4885MAPK1 935/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | KMT2A 597/4885MAPT 3971/4885MAPK1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.